IRVING TX Jan 26 MARKET WIRE DelSite Inc

The NFL deserved this, and we're all better for it.Acknowledge that Brett Favre playing on a team, any team, made the game of football better than it would have been without him, even if it eventually means another failure at the end of the season.Because right now, Favre and the Vikings are perfect. And even the strongest opposer of Favre shouldn't want that to change.. IRVING, TX, Jan 26 (MARKET WIRE) DelSite Inc. (OTCBB: DSII) today announced the termination ofmanufacturing operations at its Irving, Texas facility. Continuation ofnon-manufacturing domestic operations and manufacturing at its CostaRican plant is contingent on new funding.DelSite Biotechnologies, Inc., its wholly-owned subsidiary, received theapproval from the FDA of the Investigational New Drug (IND) application toinitiate a Phase I clinical study of the Company's lead product candidateGelVac(TM) nasal powder H5N1 (bird flu) influenza vaccine.The GelVac(TM) nasal powder platform brings distinct benefits to thevaccine products and patients. It is preservative-free, adjuvant-free andcan stabilize vaccines at room temperature for a long period of time.

Thevaccine requires no cold chain and allows needle-free administration,making it particularly well suited for influenza pandemic preparedness, aswell as controlling the seasonal influenza. Besides the pandemic influenza(H5N1), the GelVac platform is also suitable for other vaccines, includingthe seasonal flu.Once developed, this vaccine system can significantly improve and reducethe cost of individual vaccines as well as reduce the cost of stockpilingstrategic vaccines. The GelVac(TM) powder vaccine platform can be used tostabilize individual antigens as well as vaccines for extended periods oftime at room temperature. By simply being stable at room temperature,distribution logistical issues are simplified and cost reduced. Vaccinelosses caused by failures in refrigeration systems are eliminated.

Marketsunderserved because of unreliable cold chain distribution systems would beopened.Dr. Yawei Ni, Chief Scientific Officer of DelSite Biotechnologies, said,"Receiving approval of this IND is a significant milestone in advancingthe DelSite technology that can potentially revolutionize drug and vaccinedelivery. Our development team worked diligently and effectively with theFDA and satisfied all Agency's requests in a timely manner. We appreciatethe FDA's diligence in reviewing all aspects of the H5N1 antigen, nasaldelivery device used, pilot powder manufacturing process, releasespecifications for the finished vaccine and clinical protocol. We believeas does the FDA in protecting the public and extending as far as humanlypossible the safety profile of all vaccines."Dr. Ni added, "The GelVac is a very innovative and effective powderplatform; besides deliverable as a nasal powder, GelVac powder vaccinescan be reconstituted and administered using classical needle technology.Using this route of administration a strong antigen-sparing effect, i.e.,increasing numbers of vaccine doses, is created by a classical depoteffect. We believe the paradigm shift under way as to how vaccines are tobe stored, shipped and administered will be accelerated by the GelVacplatform."Mr.

Robert Schnitzius, Acting President and CEO of DelSite, commented:"The Company continues to seek outside funding and partnership for thisand other powder development projects, including the seasonal influenza,human papillomavirus (HPV) and typhoid vaccines. The survival of theCompany and initiation date of the clinical trial is contingent on whenthe Company can raise sufficient funds to continue operations andinitiate the trial. A contract research organization (CRO) has beenretained and dosing patient can begin within one month after securingadequate funding."The GelVac(TM) nasal powder is a novel, in-situ gelling powder based onDelSite's core technology, GelSite(R) polymer, which is a high molecularweight ionic polysaccharide manufactured under cGMP at kilogram scales.Based on this core technology, DelSite has developed three deliveryplatforms: 1) GelVac(TM) nasal powder for nasal delivery of vaccines andtherapeutics; 2) GelSure(TM) for injectable delivery of therapeutics; and,3) GPDA(TM) depot adjuvant for injectable delivery of vaccines.About DelSite Biotechnologies, Inc.DelSite Biotechnologies, Inc. a wholly-owned subsidiary of DelSite, Inc.,is dedicated to the delivery and stabilization of proteins and peptidesfor therapeutics and vaccines. Core platform technologyis based on a natural polysaccharide, GelSite(R) polymer.About DelSite, Inc.DelSite, Inc. is an ISO 9001-certified, research-based, biopharmaceuticaland consumer products company with a core technology based onnaturally-occurring complex carbohydrates. DelSite also manufacturesquality products for other companies Manufacturing operations comply withcGMP standards.